Viridian Therapeutics, Inc. (VRDN) stock analysis
VRDN · Viridian Therapeutics, Inc.
Latest recorded price: USD 29.80
Sector and industry: Healthcare · Biotechnology
Fiscal 2017 figures: revenue growth -14.9%, free cash flow margin -709.8%. The model flags 1 risk signal for this company (1 high severity).